Home    Back

Procedure: mesenchymal stem cell transplantation    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa1
274Osteogenesis Imperfecta1

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 147 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01033552
(ClinicalTrials.gov)		January 201014/12/2009Biochemical Correction of Severe EB by Allo HSCT and Off-the-shelf MSCsMT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and Off-the-shelf Mesenchymal Stem CellsEpidermolysis BullosaDrug: Cyclophosphamide;Drug: Fludarabine;Drug: Anti-thymocyte globulin;Drug: Cyclosporine A;Drug: Mycophenolate mofetil;Procedure: Mesenchymal stem cell transplantation;Radiation: Total body irradiation;Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantationMasonic Cancer Center, University of MinnesotaNULLRecruitingN/A25 YearsAll75Phase 2United States

274. Osteogenesis Imperfecta    [ 78 clinical trials,   87 drugs,   (DrugBank: 19 drugs),   14 drug target genes,   74 drug target pathways]
Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 78 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00705120
(ClinicalTrials.gov)		November 199523/6/2008Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow TransplantationTreatment of Severe (Types II and III) Osteogenesis Imperfecta by Allogeneic Bone Marrow TransplantationOsteogenesis ImperfectaOther: Bone Marrow Cell Transplantation;Radiation: Irradiation, Total Body;Drug: Cyclophosphamide;Drug: Cyclosporin;Procedure: Mesenchymal Stem Cell Transplantation;Drug: BusulfanSt. Jude Children's Research HospitalNULLCompleted3 YearsN/ABoth9Phase 1United States